Back

Systolic blood pressure and safety of sacubitril/valsartan in patients with heart failure

13 May 2024 (16:00 - 17:00)
Organised by: Logo
Congress Presentation Part of: ePosters in acute heart failure 12 Pharmacotherapy HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Mr Koshiro Kanaoka

National Cerebral & Cardiovascular Center, Suita (Japan)

7 More presentations in this session

Presentation thumbnail
Temporal trends in guideline-directed medical therapy prescription and 30-day readmission after heart failure hospitalization
Doctor R. Laborante (Stockholm, SE)
Abstract Slides Video
Presentation thumbnail
Unlocking stability: predictors of clinical stability in patients undergoing intermittent levosimendan infusions for advanced heart failure
Doctor F. Gerardo (Amadora, PT)
Abstract Slides Video
Presentation thumbnail
Adherence to quadruple therapy for heart failure. A single-center experience in LMIC
Doctor A. Khan (Peshawar, PK)
Abstract Slides Video
Presentation thumbnail
Impact on hospitalisation and safety of high doses of torasemide in advanced or end-stage decompensated heart failure
Doctor T. Castiello (London, GB)
Abstract Slides Video
Presentation thumbnail
Potential cardio-protective role of dapagliflozin in diabetic patients presented with anterior ST-elevation myocardial infarction (STEMI).
Associate Professor A. Ibrahim (Aswan, EG)
Abstract Slides Video

Access the full session

Session thumbnail
ePosters in acute heart failure 12

The Event

Event poster

Heart Failure 2024

13 May 2024 16:00 CET
You may be interested in
thumbnail
Congress Presentation
Left ventricular reverse remodeling following initiation of sacubitril/valsartan for heart failure with reduced ejection fraction and low blood pressure
thumbnail
Congress Presentation
Effect of initiation of sacubitril/valsartan on 24 hours blood pressure in patients with heart failure with reduced ejection fraction
thumbnail
Congress Presentation
Prospective evaluation of sacubitril/valsartan utilization patterns and clinical outcomes in Korean patients with heart failure with reduced ejection fraction: real-world post-marketing surveillance

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources